No Data
No Data
Guardant Health Presents Phase II NEO Trial Data On Guardant Reveal Tool For Organ Preservation In Node-Negative Rectal Cancer At The ASCO GI Symposium
Guardant Health to Present Data at ASCO GI Demonstrating the Value of Its Precision Oncology Tools for Cancer Detection, Treatment Decisions and Therapy Development
Barclays Initiates Guardant Health(GH.US) With Buy Rating, Announces Target Price $60
Guardant Health Initiated With an Overweight at Barclays
Guardant Health's Strategic Growth: Strong Buy Rating Amid Advancements in Reveal MRD Assay
Why Guardant Health, Inc. (GH) Soared At The Start Of The Trading Week